Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT
Condition(s):Lobular Breast CarcinomaLast Updated:November 18, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Lobular Breast CarcinomaLast Updated:November 18, 2023Recruiting
Condition(s):Pleomorphic Lobular Breast Carcinoma in Situ; Breast Florid Lobular Carcinoma in SituLast Updated:November 18, 2023Recruiting
Condition(s):Invasive Lobular Breast CarcinomaLast Updated:June 18, 2023Recruiting
Condition(s):Invasive Lobular Breast Carcinoma; ER+ Breast Cancer; HER2-negative Breast CancerLast Updated:April 18, 2023Recruiting
Condition(s):Breast CancerLast Updated:August 12, 2013Unknown status
Condition(s):Breast Cancer; Lobular Carcinoma; Invasive Breast CancerLast Updated:July 2, 2021Completed
Condition(s):Breast Atypical Hyperplasia; Breast Lobular Carcinoma in Situ; Breast Atypical Lobular HyperplasiaLast Updated:February 5, 2024Recruiting
Condition(s):Atypical Hyperplasia of the Breast; Lobular Breast Carcinoma In Situ; Pleomorphic Lobular Breast Carcinoma In SituLast Updated:March 22, 2024Recruiting
Condition(s):Lobular Breast Carcinoma; CDH1 Gene InactivationLast Updated:September 21, 2023Active, not recruiting
Condition(s):Atypical Lobular Hyperplasia; Atypical Ductal Hyperplasia; Lobular Carcinoma in SituLast Updated:October 10, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.